Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges

Autor:	Houria Boulaiz, Eduardo Martínez-Molina, Daniel Martínez-Moreno, Juan A. Marchal, Carlos Chocarro-Wrona
Rok vydání:	2020
Předmět:	Computer science Genetic enhancement Bioreactor lcsh:RS1-441 Pharmaceutical Science Gene transfer Computational biology Review Viral vector lcsh:Pharmacy and materia medica 03 medical and health sciences bioreactor Gene therapy 0302 clinical medicine Production (economics) Good manufacturing practice 030304 developmental biology 0303 health sciences biology Gene carrier Scale (chemistry) lentiviral vector Large-scale production biology.organism_classification gene therapy large-scale production 030220 oncology & carcinogenesis Lentivirus Lentiviral vector
Zdroj:	Pharmaceutics Digibug: Repositorio Institucional de la Universidad de Granada Universidad de Granada (UGR) Pharmaceutics, Vol 12, Iss 1051, p 1051 (2020) Digibug. Repositorio Institucional de la Universidad de Granada instname
ISSN:	1999-4923 0089-2017
Popis:	Lentiviral vectors (LVs) have gained value over recent years as gene carriers in gene therapy. These viral vectors are safer than what was previously being used for gene transfer and are capable of infecting both dividing and nondividing cells with a long-term expression. This characteristic makes LVs ideal for clinical research, as has been demonstrated with the approval of lentivirus-based gene therapies from the Food and Drug Administration and the European Agency for Medicine. A large number of functional lentiviral particles are required for clinical trials, and large-scale production has been challenging. Therefore, e orts are focused on solving the drawbacks associated with the production and purification of LVsunder current good manufacturing practice. In recent years, we have witnessed the development and optimization of new protocols, packaging cell lines, and culture devices that are very close to reaching the target production level. Here, we review the most recent, e cient, and promising methods for the clinical-scale production ofLVs. Fundación Empresa Universidad de Granada PR/18/001 Instituto de Salud Carlos III FMM-AP16683-2017 Junta de Andalucía PI-0089-2017 Chair "Doctors Galera-Requena in cancer stem cell research" Consejería de Economía, Conocimiento, Empresas y Universidades de la Junta de Andalucía (FEDER Funds) SOMM17/6109/UGR
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::488d61c3b15969152ec8a8befb3824f1 https://pubmed.ncbi.nlm.nih.gov/33153183 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.